Patents Assigned to Innogenetics N.V.
-
Publication number: 20060093617Abstract: The present invention is directed to peptides, and nucleic acids encoding them, derived from the Hepatitis C Virus (HCV). The peptides are those which elicit a CTL and/or HTL response in a host. The invention is also directed to compositions and vaccines for prevention and treatment of HCV infection and diagnostic methods for detection of HCV exposure in patients.Type: ApplicationFiled: May 31, 2005Publication date: May 4, 2006Applicants: Innogenetics, N.V., EPIMMUNE INC.Inventors: Marie-Ange Buyse, Geert Maertens, Erik Depla, Ignace Lasters, Johan Desmet, Denise Baker, Robert Chesnut, Mark Newman, Alessandro Sette, John Sidney, Scott Southwood
-
Patent number: 7026457Abstract: The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and/or E1/E2 characterized in that upon lysing the transformed host cells to isolate the recombinantly expressed protein a disulphide bond cleavage or reduction step is carried out with a disulphide bond cleavage agent. The present invention also relates to a composition isolated by such a method. The present invention also relates to the diagnostic and therapeutic application of these compositions. Furthermore, the invention relates to the use of HCV E1 protein and peptides for prognosing and monitoring the clinical effectiveness and/or clinical outcome of HCV treatment.Type: GrantFiled: October 10, 2001Date of Patent: April 11, 2006Assignee: Innogenetics N.V.Inventors: Geert Maertens, Fons Bosman, Guy De Martynoff, Marie Ange Buyse
-
Publication number: 20060039989Abstract: The present invention relates to a pharmaceutical composition comprising a non-viable cell lysate and at least one antiflocculant and/or antisedimentation agent(s). The pharmaceutical composition of the present invention comprising the cell lysate is in the form of a solution or a suspension or a lyophilisate, in particular, the homogenized cell lysate compositions are in the form of solutions or suspensions or lyophilisates. The present invention further discloses processes for the production and the use of the pharmaceutical composition.Type: ApplicationFiled: November 25, 2003Publication date: February 23, 2006Applicant: Innogenetics N.V.Inventors: Chris Vervaet, Jean-Paul Remon, Bernard Delaey, Peter De Waele
-
Publication number: 20060034861Abstract: The invention relates to recombinantly or synthetically produced HCV E1 envelope proteins or parts thereof comprising disulfides between specific cysteine residues. The invention further relates to viral-like particles and compositions comprising said HCV E1 envelope proteins or parts thereof as well as to methods using said HCV E1 envelope proteins or parts thereof, and to kits comprising said HCV E1 envelope proteins or parts thereof.Type: ApplicationFiled: March 8, 2005Publication date: February 16, 2006Applicant: INNOGENETICS N.VInventors: Stany Depraetere, Erik Depla, Gert Verheyden, Alfons Bosman
-
Patent number: 6974864Abstract: The present invention relates to new genomic nucleotide sequences and amino acid sequences corresponding to the coding region of these genomes. The invention relates to new HCV types and subtypes sequences which are different from the known HCV types and subtypes. More particularly, the present invention relates to new HCV type 7 sequences, new HCV type 9 sequences, new HCV type 10 and new HCV type 11 sequences. Also, the present invention relates to new HCV type 1 sequences of subtypes 1d, 1e, 1f and 1g; new HCV type 2 sequences of subtypes 2e, 2f, 2g, 2h, 2I, 2k and 2l; new HCV type 3 sequences of subtype 3g, new HCV type 4 sequences of subtypes 4k, 4l and 4m; a process for preparing them, and their use for diagnosis, prophylaxis and therapy. More particularly, the present invention provides new type-specific sequences of the Core, the E1 and the NS5 regions of new HCV types 7, 9, 10 and 11, as well as of new variants (subtypes) of HCV types 1, 2, 3 and 4.Type: GrantFiled: May 9, 2001Date of Patent: December 13, 2005Assignee: Innogenetics N.V.Inventors: Geert Maertens, Lieven Stuyver
-
Publication number: 20050142575Abstract: The present invention relates to 16S-23S rRNA spacer sequences from Staphylococcus aureus and their use in a method for detection and/or identification of Staphylococcus aureus. The invention further relates to a method for detection and identification of Staphylococcus aureus in a sample, involving the steps of: (i) optionally releasing, isolating and/or concentrating the polynucleic acids present in the sample; (ii) optionally amplifying the 16S-23S rRNA spacer region, or a part thereof, with at least one primer pair; (iii) detecting the presence of a 16S-23S rRNA spacer sequence; and (iv) identifying the Staphylococcus aureus present in the sample from the nucleic acid(s) detected in the sample.Type: ApplicationFiled: July 21, 2004Publication date: June 30, 2005Applicant: INNOGENETICS N.V.Inventors: Geert Jannes, Rudi Rossau, Hugo Van Heuverswyn
-
Patent number: 6890737Abstract: The present invention relates to a method for purifying recombinant HCV single or specific oligomeric envelope proteins selected from the group consisting of E1 and/or E1/E2, characterized in that upon lysing the transformed host cells to isolate the recombinantly expressed protein a disulphide bond cleavage or reduction step is carried out with a disulphide bond cleavage agent. The present invention also relates to a composition isolated by such a method. The present invention also relates to the diagnostic and therapeutic application of these compositions. Furthermore, the invention relates to the use of HCV E1 protein and peptides for prognosing and monitoring the clinical effectiveness and/or clinical outcome of HCV treatment.Type: GrantFiled: September 12, 1997Date of Patent: May 10, 2005Assignee: Innogenetics N.V.Inventors: Geert Maertens, Fons Bosman, Guy De Martynoff, Marie-Ange Buyse
-
Patent number: 6891026Abstract: The invention relates to a process for genotyping any HCV isolate present in a biological sample, previously identified as being HCV positive, and for classifying said isolate according to the percentage of homology with other HCV isolates, comprising the steps of: contacting said sample in which the ribonucleotides or deoxyribonucleotides have been made accessible, if need be, under suitable denaturation, with at least one probe from about 10 to about 40 nucleotides, with said probe being liable to hybridize to a region being in the domain extending from nucleotide at position ?291 to nucleotide at position ?66 of the 5? untranslated region of one of the HCV isolates represented by their cDNA sequences, with said numbering of position beginning with the first ATG codon of the open reading frame encoding the HCV polyprotein, or with said probe being complementary to the above-defined probes, detecting the complexes possibly formed between said probe and the nucleotide sequence of the HCV isolate to be idenType: GrantFiled: July 6, 2001Date of Patent: May 10, 2005Assignee: Innogenetics N.V.Inventors: Geert Maertens, Lieven Stuyver, Rudi Rossau, Hugo Van Heuverswyn
-
Patent number: 6887985Abstract: The invention relates to a process for genotyping any HCV isolate present in a biological sample, previously identified as being HCV positive, and for classifying said isolate according to the percentage of homology with other HCV isolates, comprising the steps of: contacting said sample in which the ribonucleotides or deoxyribonucleotides have been made accessible, if need be, under suitable denaturation, with at least one probe from about 10 to about 40 nucleotides, with said probe being liable to hybridize to a region being in the domain extending from nucleotide at position ?291 to nucleotide at position ?66 of the 5? untranslated region of one of the HCV isolates represented by their cDNA sequences, with said numbering of position beginning with the first ATG codon of the open reading frame encoding the HCV polyprotein, or with said probe being complementary to the above-defined probes, detecting the complexes possibly formed between said probe and the nucleotide sequence of the HCV isolate to be idenType: GrantFiled: July 6, 2001Date of Patent: May 3, 2005Assignee: Innogenetics N.V.Inventors: Geert Maertens, Lieven Stuyver, Rudi Rossau, Hugo Van Heuverswyn
-
Patent number: 6872520Abstract: Peptide sequences are provided which are capable of mimicking proteins encoded by HCV for use as reagents for screening of blood and blood products for prior exposure to HCV. The peptides are at least 5 amino acids long and can be used in various specific assays for the detection of antibodies to HCV, for the detection of HCV antigens, or as immunogens.Type: GrantFiled: January 15, 2002Date of Patent: March 29, 2005Assignee: Innogenetics N.V.Inventors: Robert J. DeLeys, Dirk Pollet, Geert Maertens, Hugo Van Heuverswijn
-
Patent number: 6858387Abstract: The current invention relates to the field of detection and identification of clinically important fungi. More particularely, the present invention relates to species specific probes originating from the Internal Transcribed Spacer (ITS) region of rDNA for the detection of fungal species such as Candida albicans, Candida parapsilosis, Candida tropicalis, Candida kefyr, Candida krusei, Candida glabrata, Candida dubliniensis, Aspergillus flavus, Aspergillus versicolor, Aspergillus nidulans, Aspergillus fumigatus, Cyptococcus neoformans and Pneumocystis carinii in clinical samples, and methods using said probes.Type: GrantFiled: September 15, 2000Date of Patent: February 22, 2005Assignees: Innogenetics, N.V., Enterprise IrelandInventors: Terry Smith, Majella Maher, Cara Martin, Geert Jannes, Rudi Rossau, Marjo Van Der Weide
-
Publication number: 20050014136Abstract: The present invention relates to peptides or polypeptides comprising an HCV NS5 protein or a part thereof or a derivative of said peptide or polypeptide, HCV NS5 protein or part thereof wherein at least one cysteine is reversibly or irreversibly modified. These modified HCV NS5 proteins have advantageous properties both for diagnostic and therapeutic/prophylactic applications.Type: ApplicationFiled: May 28, 2004Publication date: January 20, 2005Applicant: INNOGENETICS N.V.Inventors: Erik Depla, Geert Maertens, Fons Bosman
-
Patent number: 6841353Abstract: Antibodies to two new epitopes on the HCV envelope proteins were identified which allow routine detection of native HCV envelope antigens, in tissue or cells derived from the host. The new epitopes are: the E1 region aa 307-326 and the N-terminal hyper variable region of E2 aa 395-415. Surprisingly, we characterised an antibody that reacts with various sequences of the hypervariable domain of E2. Specific monoclonal antibodies directed against these epitopes and allowing routine detection of viral antigen are described.Type: GrantFiled: December 13, 2002Date of Patent: January 11, 2005Assignee: Innogenetics N.V.Inventors: Geert Maertens, Erik Depla, Marie-Ange Buyse
-
Patent number: 6830752Abstract: The present invention concerns molecules which bind and neutralize the cytokine interferon-gamma. More specifically, the present invention relates to sheep-derived antibodies and engineered antibody constructs, such as humanized single-chain Fv fragments, chimeric antibodies, diabodies, triabodies, tetravalent antibodies, peptabodies and hexabodies which can be used to treat diseases wherein interferon-gamma activity is pathogenic. Examples of such diseases are: septic shock, cachexia, multiple sclerosis and psoriasis.Type: GrantFiled: February 7, 2002Date of Patent: December 14, 2004Assignee: Innogenetics N. V.Inventors: Marie-Ange Buyse, Erwin Sablon
-
Patent number: 6811978Abstract: The present invention relates to 16S-23S rRNA spacer sequences from Pseudomonas species and their use in a method for detection and/or identification of Pseudomonas species. The invention further it relates to a method for detection and identification of at least one Pseudomonas species, or for the simultaneous detection of several Pseudomonas species in a sample, involving the steps of: (i) optionally releasing, isolating and/or concentrating the polynucleic acids present in the sample; (ii) optionally amplifying the 16S-23S rRNA spacer region, or a part thereof, with at least one primer pair; (iii) detecting the presence of a 16S-23S rRNA spacer sequence; and (iv) identifying the Pseudomonas species present in the sample from the nucleic acid(s) detected in the sample.Type: GrantFiled: August 17, 2001Date of Patent: November 2, 2004Assignee: Innogenetics N.V.Inventors: Geert Jannes, Rudi Rossau, Hugo Van Heuverswyn
-
Patent number: 6803187Abstract: The present invention relates to a method for the rapid and reliable detection of drug-selected mutations in the HIV protease gene allowing the simultaneous charaterization of a range of codons involved in drug resistance using specific sets of probes optimized to function together in a reverse-hybridization assay.Type: GrantFiled: June 25, 2001Date of Patent: October 12, 2004Assignee: Innogenetics N.V.Inventor: Lieven Stuyver
-
Publication number: 20040185061Abstract: The present invention relates to HCV proteins in which cysteine residues are reversibly protected during purification. Eventually, this purification procedure results in HCV proteins with biological activity and a native-like protein conformation, which present corresponding epitopes. The present invention pertains also to drug screening methods using these HCV proteins, and diagnostic and therapeutic applications, such as vaccines and drugs.Type: ApplicationFiled: April 16, 2004Publication date: September 23, 2004Applicant: Innogenetics N.V.Inventors: Alfons Bosman, Erik Depla, Geert Maertens
-
Publication number: 20040091942Abstract: The present invention provides a method for the diagnosis of tauopathies in an individual and/or for the differential diagnosis of a tauopathy versus a non-tauopathy based on the detection of the ratio of phospho-tau (181)/total tau in said individual. The present invention further provides a phospho-peptide for standardization in a method of the invention.Type: ApplicationFiled: October 9, 2003Publication date: May 13, 2004Applicant: INNOGENETICS N.V.Inventors: Eugeen Vanmechelen, Hugo Vanderstichele
-
Patent number: 6713251Abstract: The present invention relates to a method for the rapid and reliable detection of drug-induced mutations in the reverse transcriptase gene allowing the simultaneous characterization of a range of codons involved in drug resistance using specific sets of probes optimized to function together in a reverse-hybridization assay.Type: GrantFiled: August 31, 2001Date of Patent: March 30, 2004Assignee: Innogenetics N.V.Inventors: Lieven Stuyver, Joost Louwagie, Rudi Rossau
-
Patent number: 6709812Abstract: The present invention relates to a method for detection and/or genetic analysis of HBV in a biological sample, comprising hybridizing the polynucleic acids of the sample with a combination of at least two nucleotide probes, with said combination hybridizing specifically to a mutant target sequence chosen from the HBV RT pol gene region and/or to a mutant target sequence chosen from the HBV preCore region and/or to a mutant target sequence chosen from the HBsAg region of HBV and/or to a HBV genotype-specific target sequence, with said target sequences being chosen from FIG.Type: GrantFiled: October 8, 1998Date of Patent: March 23, 2004Assignee: Innogenetics N.V.Inventors: Lieven Stuyver, Rudi Rossau, Geert Maertens